Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Director J. Erik Fyrwald acquired 17 shares of Eli Lilly stock at $579.76 per share through a deferral plan.

Summary

• J. Erik Fyrwald, a director at Eli Lilly & Co, acquired 17 shares of common stock on December 18, 2023.
• The shares were acquired at a price of $579.76 each.
• These shares were obtained through the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock after Mr. Fyrwald's separation from service.
• Following this transaction, Mr. Fyrwald directly owns 71,886 shares of Eli Lilly stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it shows director confidence, but it is not a major event.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

This is a routine transaction for a company director, and is not unusual in the pharmaceutical industry.

Comparison to Industry Standards

• Director share acquisitions are common across publicly traded companies, including pharmaceutical companies like Pfizer (PFE) and Johnson & Johnson (JNJ).
• These transactions are often part of compensation packages or deferral plans, similar to what is described in this document.
• The number of shares acquired is relatively small compared to the total outstanding shares of Eli Lilly, which is typical for individual director transactions.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates director confidence in the company.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Ownership, LLY